Travere Therapeutics (Bile Acid Product Portfolio) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Travere Therapeutics (Bile Acid Product Portfolio) General Information

Description

A pharmaceutical product portfolio for the treatment of rare liver diseases based in San Diego, California. Cholbam is indicated for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease and Chenodal is indicated for the treatment of radiolucent stones in the gallbladder, which is also under Phase 3 clinical evaluation for cerebrotendinous xanthomatosis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • San Diego, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Mirum Pharmaceuticals
Corporate Office
  • San Diego, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Travere Therapeutics (Bile Acid Product Portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Travere Therapeutics (Bile Acid Product Portfolio)‘s full profile, request access.

Request a free trial

Travere Therapeutics (Bile Acid Product Portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Travere Therapeutics (Bile Acid Product Portfolio)‘s full profile, request access.

Request a free trial

Travere Therapeutics (Bile Acid Product Portfolio) FAQs

  • Where is Travere Therapeutics (Bile Acid Product Portfolio) headquartered?

    Travere Therapeutics (Bile Acid Product Portfolio) is headquartered in San Diego, CA.

  • What industry is Travere Therapeutics (Bile Acid Product Portfolio) in?

    Travere Therapeutics (Bile Acid Product Portfolio)’s primary industry is Buildings and Property.

  • Is Travere Therapeutics (Bile Acid Product Portfolio) a private or public company?

    Travere Therapeutics (Bile Acid Product Portfolio) is a Private company.

  • What is the current valuation of Travere Therapeutics (Bile Acid Product Portfolio)?

    The current valuation of Travere Therapeutics (Bile Acid Product Portfolio) is .

  • What is Travere Therapeutics (Bile Acid Product Portfolio)’s current revenue?

    The current revenue for Travere Therapeutics (Bile Acid Product Portfolio) is .

  • Who are Travere Therapeutics (Bile Acid Product Portfolio)’s investors?

    Travere Therapeutics has invested in Travere Therapeutics (Bile Acid Product Portfolio).

  • When was Travere Therapeutics (Bile Acid Product Portfolio) acquired?

    Travere Therapeutics (Bile Acid Product Portfolio) was acquired on 16-Jul-2023.

  • Who acquired Travere Therapeutics (Bile Acid Product Portfolio)?

    Travere Therapeutics (Bile Acid Product Portfolio) was acquired by Mirum Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process